D. Margolskee

发表

Release of cyclooxygenase products from primary cultures of tracheal epithelia of dog and human.

J. Nadel, J. Widdicombe, I. Ueki, 1989, The American journal of physiology.

Urinary LTE4 excretion in antigen‐provoked asthmatic patients treated with the inhaled LTD4 antagonist, L‐648,051

D. Margolskee, P. Tagari, Y. Girard, 1992, Allergy.

676 A potent leukotriene D4 (LTD4) antagonist (MK-571) significantly reduces airway obstruction in mild to moderate asthma

W. Busse, D. Margolskee, V. Williams, 1991 .

677 The therapeutic effects of MK-571, a potent and selective leukotriene (LT) D4 receptor antagonist, in patients with chronic asthma

S. Spector, R. Dockhorn, E. Israel, 1991 .

MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.

R. Pauwels, G. Joos, D. Margolskee, 1991, The American review of respiratory disease.

The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.

J. Curtis, P. Hopewell, D. Margolskee, 2015, The American review of respiratory disease.

Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers.

D. Margolskee, D. Schoors, P. Larson, 1995, British journal of clinical pharmacology.

Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man

D. Margolskee, A. Hecken, M. Depré, 2005, European Journal of Clinical Pharmacology.

Dose-dependent kinetics of the enantiomers of MK-571, an LTD4-receptor antagonist

D. Margolskee, A. Hecken, M. Depré, 2005, European Journal of Clinical Pharmacology.

Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.

P. O'Byrne, R. Watson, D. Margolskee, 1990, The New England journal of medicine.

Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.

D. Margolskee, T. Bjornsson, J. Schwartz, 1993, British journal of clinical pharmacology.

Leukotriene (LT) D4 Is Involved in Antigen‐Induced Asthma: a Study with the LTD4 Receptor Antagonist, MK‐571

D. Margolskee, K. Andersson, K. Andersson, 1991, Annals of the New York Academy of Sciences.

Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.

W. Busse, R. Bush, D. Margolskee, 1992, The American review of respiratory disease.

Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma.

D. Margolskee, P. Tagari, K. Andersson, 1992, The Journal of allergy and clinical immunology.

Clinical Experience with MK‐571

D. Margolskee, 1991 .

Indomethacin blocks airway tolerance to repetitive exercise but not to eucapnic hyperpnea in asthmatic subjects.

H. Boushey, D. Margolskee, B. Bigby, 1988, The American review of respiratory disease.

Monitoring Changes in Serum Albumin (SA) Concentrations As an Early and Objective Indicator of Potential CMX001-Associated Gastrointestinal (GI) Adverse Drug Effects

D. Margolskee, T. Brundage, H. Momméja-Marin, 2013 .

Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.

S. Dahlén, B. Dahlén, D. Margolskee, 1993, Thorax.

The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

S. Dahlén, B. Dahlén, D. Margolskee, 1993, The European respiratory journal.

Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist.

D. Margolskee, 1991, Annals of the New York Academy of Sciences.

CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK Virus (BKV) Associated Bladder and Kidney End-Organ Damage: 2576

M. Boeckh, D. Margolskee, F. Marty, 2012 .